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Introduction 
By definition research and development (R&D) is a process of creating new products, 
processes and technologies that can be used and marketed for mankind’s benefit in 
the future.  
Factors influencing R&D activity 
1. R&D expenditure 
The R&D growth is driven by the country’s economic strength and growth which is 
measured by the gross domestic product (GDP). In the last decade there was a serious 
global decrease in funding due to several reasons including the global financial crisis 
from 2008 through 2010 affecting seriously both central and industrial funding of 
research. 
The latest global evaluation and forecast done by the Industrial Research Institute (IRI) 
is positive about future R&D spending increase, rising attitude towards partnerships 
and improving overall health of global economy. [1] The growth in global R&D 
investments is based on growing spending in Asian countries, especially in China. 
Asian R&D spending has a 41% share in global spending and increasing while North 
America and Europe has a 28% and 21% respectively and declining, but globally the 
USA is still the largest single country in R&D spending. China’s total R&D expenditure 
is expected to exceed that of the USA’s by 2019. Concerning Europe, Germany, 
France and the UK are in the forefront of R&D spending [2]. 
The total global R&D spending was $1,805 billion in 2014, the United States having a 
26.9% share with $485 billion, while Europe’s share and spending was 21.5% and 
$388 billion.  
Health related R&D is 10 to 20% of total R&D expenditure in the majority of the 
countries. There are some exceptions though, the most extreme is Switzerland with 
40.6% and Russia with its 3.2% (Table 1).  
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Table 1. Total R&D and health related R&D Expenditures.  
Data source: World Health Organization (WHO), Global Observatory, Health R&D, http://gohrd.azurewebsites.net/Country 
The largest investor into and key player in health related R&D is the USA. However, 
the business investment have strongly declined in the last decade and governmental 
investment, trying to compensate is limited. There are also uncertainty in the future of 
healthcare companies with the changing political environment. Still, the investment is 
expected to grow.   
The second largest investor into R&D is China. Concerning China’s health related R&D 
spending, there is no data available in WHO Global Observatory, but definitely there is 
a strong will in China to become a key leader in health related R&D and innovation in 
the future. This effort manifested in 1) spending 1.17 billion USD for promoting life and 
2012 (in billion PPP dollars) Total R&D Health related R&D As % of total R&D
USA 453.54 105.82 23.3%
China 257.00
Japan 151.02 21.96 14.5%
Germany 96.46 13.46 14.0%
UK 38.39 9.83 25.6%
France 54.26 8.43 15.5%
South Korea 64.05 7.62 11.9%
India 40.24 5.82 14.5%
Canada 25.05 5.48 21.9%
Switzerland 13.04 5.30 40.6%
Italy 26.67 4.12 15.4%
Spain 19.17 3.77 19.7%
Australia 21.23 3.76 17.7%
Sweden 13.37 2.52 18.9%
Netherlands 14.60 2.37 16.2%
Turkey 12.40 2.03 16.4%
Denmark 7.24 1.97 27.2%
Russia 37.85 1.23 3.2%
Poland 7.74 1.02 13.1%
Norway 5.06 0.93 18.3%
Hungary 2.85 0.74 25.9%
Finland 7.38 0.69 9.3%
Czech Republic 5.33 0.44 8.3%
Romania 1.74 0.17 9.8%
Croatia 0.66 0.17 25.8%
Ukrain* 2.80 0.14 5.0%
Slovakia 1.13 0.11 10.0%
Serbia* 0.66 0.08 12.6%
Estonia 0.70 0.06 7.9%
Latvia 0.41 0.04 10.8%
Belorussia 1.08 0.04 3.6%
Lithuania 0.19 0.02 12.3%
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medical sciences in 2012, 2) the state investing 1.1 billion USD in new drug 
development between 2011-2015, 3) growing number of researchers return from 
overseas with training in biomedical sciences, 4) more than three hundred clinical 
research organizations (CRO) providing preclinical and clinical research services to 
pharmaceuticals, presenting a pharmaceutical R&D innovation potential, 5) lifting price 
controls on hundreds of western medications by the government in 2015 or 6) fighting 
with corruption in the drug registration process [3]. Despite all these efforts, there are 
still ways to improve the education system repressing creativity, to shorten the new 
drug registration process, which is extremely long, to solve product safety issues and 
improve the intellectual property regulations. Still, forecasts expect China to become 
the number one player in health related R&D in the near future, however different 
forecasts expect it to happen within different time frames [1, 2]. 
In Europe, Germany, France, UK, Switzerland and Spain are the largest health related 
R&D spenders. Northern European countries are emerging from smaller countries 
thanks to their more intense investments in research and education. Remarkably, 
Central and Eastern European countries have little sources for health-related R&D.  
2. Human Resources 
Beyond financial resources, investing in human capital is key to innovation and 
economic development. The USA has an education system traditionally supporting 
creativity and innovation.  As it is mentioned earlier, this is not the case in China. Also, 
in Europe, especially in Central-Eastern Europe there is a lot to do to improve the 
education. The European Union regards the human resource development in R&D as 
priority and started several initiatives like the European Research Area (ERA), the 
Framework programs, the Innovative Union or the Scientific Advice Mechanism (SAM) 
to support the European research system. Research and Development Statistics 
(based on the data reported to OECD and Eurostat in the framework of the joint 
OECD/Eurostat international data collection on resources devoted to R&D) show that 
Israel, Korea, Japan, Sweden, Finland and Denmark had the highest R&D intensity 
(gross domestic expenditure on R&D in percentage of the GDP) and the highest 
number of researchers per 1000 employments in 2014, while China had almost the 
lowest number of researchers per 1000 employments. This is an area where China 
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could improve substantially and it is expected to do so. Central Eastern European 
Countries are in the last third of the countries in both parameters [2]. 
The Global Talent Index is representing a countries potential to develop, attract and 
retain talent, measured by demographic trends, educational infrastructure, quality of 
the labor force and the ability of a country’s economy to foster competitive and 
internationally-oriented environment [4]. 
The US is ranking first in Global Talent Index (GTI) thanks to its excellent universities 
and the high overall quality of its workforce. We can find also the Nordic countries 
(Denmark, Finland, Sweden, Norway) and the developed Asia Pacific countries 
(Australia and Singapore) in the top ten, this result derives from the substantial 
investment in education or openness to foreign investments. China is 31st but the pace 
of improvement between 2011 and 2015 is the highest among the sixty countries in 
the index. The Czech Republic, Poland, Slovakia and Hungary are between the 25th -
30th places in this order. 
3. Other important factors influencing R&D activity 
Because of the limited space in this work, I decided to summarize the other, also 
important factors influencing R&D activity. The political environment defines the actual 
priorities for the nation and the general attitude towards research. Action plans, 
stakeholder associations, patient organizations may influence political and economic 
decisions by collecting and disseminating information, effectively representing a 
society with the same interest and publishing white papers to draw the attention to 
important research or other healthcare areas to be supported. 
The regulatory framework may support or impede improvement. The length and 
transparency of China’s new drug registration process or the under regulated 
intellectual property protection were mentioned earlier as negative examples.  
The underdeveloped infrastructure could be a limiting factor in innovation as well.  
The health related R&D needs are need to be defined also by the global disease 
burden providing more funds to low and middle income countries to struggle with 
diseases relevant to them [5].  
Concluding, the environment influencing health related R&D is very complex and 
multifactorial, thus there are several possibilities to improve the situation. 
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Aims 
I. To understand the research trends in the field of gastroenterology and highlight the 
most endangered areas based on the gastrointestinal research publications in the last 
50 years. 
 
II. To identify possibilities of developing a better environment for pancreatic research 
and improvement of patient care within the framework of the Hungarian Pancreatic 
Study Group. 
 Patient registries – building registries and biobanks in acute pancreatitis (AP), 
chronic pancreatitis (CP) and pancreatic cancer (PC) – prospectively collecting 
clinical data to understand the development of the diseases, to monitor current 
diagnostic and therapy practices. Biobanks – collecting biological samples to 
explore the genetic background of the diseases. 
o Developing the protocol, questionnaires, other documents for the patient 
registries and biobanks. 
o Developing the webpage and electronic data administration system for 
the patient registries. 
o Enrolling healthcare centers to become multicentre.  
o Elaborating the way of data quality control and data curation.  
o Providing a platform for research ideas in pancreatology. Developing 
research collaborations. 
o Becoming multinational, multicentre 
 EBM guidelines 
o Adaptation of existing international guidelines 
o Organizing a consensus meeting 
 Education of doctors and students 
o Publishing guidelines 
o Presentation of guidelines 
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Understanding the research trends in 
gastroenterology 
Background 
As the USA is the largest single country in R&D spending, we started the evaluation of 
the R&D spending structure there. Four major players are sponsoring biomedical 
research in the USA (and in most of the countries with minor alterations): federal 
government (through NIH), state and local governments, private non-profit 
organizations (including foundations) and industry. Global biomedical research funding 
has started decreasing in the 21st century. The budget for the NIH, which is the largest 
contributor to biomedical research, has increased by an annual growth rate of 7.8% for 
1994-2003, followed by an annual growth rate of 3.4% for 2003-2007, then started to 
decrease by 2.0% in 2008 [6-8]. The American Recovery and Reinvestment Act 
pumped $10 billion into the NIH in 2009-2010 compensating the losses due to the 
financial crisis, but traditional federal funding was declining further through 2014 [1]. 
Moreover, data on corporate investment trends published by the Biotechnology 
Industry Organization in February 2015 showed a general decrease (from $21 billion 
(2004–2008) to $17 billion (2009–2013)) in research investment in novel drug R&D 
and drug improvement R&D [9]. However, investment trends in the different disease 
categories have been highly variable. The top funded disease area was oncology with 
its 24% of venture funding share in the last 10 years, followed by Neurology and 
Infectious Diseases with 12.1% and 10.9% respectively. On the contrary, financing for 
Psychiatry, Gastrointestinal and Respirators Diseases altogether made up less than 
10% of the total spending. Shockingly, the biggest drop was in the area of 
gastroenterology disease (62% from $828 million to $311 million), a wake-up call to 
academic researchers to boost research activity in the field. Since academic research 
usually provides the basis for industrial R&D, our aim was to understand the research 
trends in the field of gastroenterology and highlight the most endangered areas. 
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Evaluating scientific activity 
Sciences use tools and resources like scientists, money and time to produce scientific 
knowledge with outcome oriented goals like benefitting health, preventing disease and 
return on investment (Figure 1). 
 
Figure 1. Scientific production process 
 
Though, it has its limitations described later, scientific knowledge can be represented 
by publications in the scientific literature. 
Based on a PubMed count of biomedical publications, general trends of biomedical 
scientific literature show that both publication number and author number have risen 
exponentially between 1965 and 2014. Moreover, the average number of authors per 
publication has more than doubled, the number of scientific journals has tripled since 
1965 [6]. In this growing environment we tried to flashlight the basic facts and shares 
within gastroenterology and pancreatology. 
 
Methods 
1. Analyzing scientific activity in the different areas of 
gastroenterology 
In the first part of the study, we searched PubMed hits between 1965 and 2015 for 
pancreatic diseases (diabetes, pancreatitis and pancreatic cancer); benign 
gastrointestinal (GI) diseases, such as upper GI tract disorders (reflux, oesophagitis, 
Barrett’s syndrome and gastritis), lower GI tract diseases (inflammatory bowel 
diseases and irritable bowel syndrome) and hepatitis; and malignant GI diseases, such 
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as gastric, oesophageal, colon, liver and pancreatic cancers. Altogether, 1,554,325 
articles were analyzed. 
 
2. Detailed analyses of basic and clinical studies on pancreatitis and 
pancreatic cancer 
Since the biggest drop in research activity was in pancreatology, in the second part of 
the study we aimed to search PubMed for ‘experimental pancreatitis’ (E-P; 3,767 
articles were found), ‘experimental pancreatic cancer’ (E-PC; 3,697 articles), 
‘pancreatitis AND clinical trial’ (C-P; 2,470), ‘pancreatic cancer AND clinical trial’ (C-
PC; 4,321). Altogether, 14,255 articles were analyzed. All the available abstracts were 
checked. The final analyses were only performed on articles which contained original 
data in pancreatic research (6,628) in the categories described above. After the 
exclusions, we conducted a detailed analysis of 1,871 articles in E-P, 1,726 in E-PC, 
1,079 in C-P and 1,952 in C-PC. The following parameters were collected from the 
articles: (1) number of countries and (2) countries, (3) number of centres involved in 
the research, (4) the journal’s impact factor (IF; based on the last available IF for the 
journal) and (5) whether the trial was registered in an official trial registry (only for 
clinical trials). An article was defined as ‘multinational’ if more than five countries were 
involved in the study and ‘multicentre’ if more than five centres took part. Analyses 
were performed for individual countries. An analysis of the individual parameters was 
conducted on the group of articles where the given parameter was available.  
All PubMed searches took place on 23 December 2015. 
 
Limitations  
Counting publication and citation numbers and impact are designed to measure 
scientific efficiency and productivity but recent studies raised concerns about the 
quality of biomedical literature claiming that irreproducibility and lack of transparency 
are the main problems [6]. Also, without thoroughly studying of outcomes, it is 
impossible to evaluate the efficiency of scientific activity, but estimating the output may 
provide a crude picture of scientific activity in the field.  
The search was performed in PubMed, which provides a substantial selection of 
scientific literature, but of course it does not provide full coverage of all scientific 
activity.  
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Another limitation was the lack of information on specific parameters in some of the 
individual abstracts. These abstracts were excluded from the analysis of that particular 
parameter.  
Finally, due to the extremely high number of articles, the impact factors (IF) of the 
articles were not calculated for the year of publication, but based on the journal’s IF for 
the most recent year (2014). 
 
3. Statistical analysis 
To investigate differences in research activity, we compared the confidence intervals 
(CI) of the proportions. We used the equation for large samples, 
𝑝∗ ± 𝑧 × √
𝑝∗×(1−𝑝∗)
𝑛
, where 𝑝∗ =
𝑚
𝑛
, m=number of articles/disease and n=number of all 
articles. 
To analyze the changes of research activity, we compared the slopes of the regression 
with an estimation of CI. One-way ANOVA was used with Dunnett’s post hoc test 
(unequal variances were assumed) to compare the IF between countries and centres. 
Chi-square tests were employed for relationship analysis. Statistical analyses were 
done by IBM SPSS Statistics v 20.0 (IBM Corporation, Armonk, NY, USA). 
Values are expressed as means ± standard error (S.E.M.) if not stated otherwise. A P 
value <0.05 was considered statistically significant.   
 
Results  
1. Research activity on pancreatitis has decreased compared to other 
gastrointestinal diseases 
In the first part of the study, we characterized research activity on different parts of the 
GI tract. In 1965, among the major benign GI disorders, 51.9% (CI 49.58–54.22) of the 
research was performed on hepatitis, 25.7% (CI 23.63–27.75) on pancreatitis, 21.7% 
(CI 19.76–23.30) on upper GI diseases and only 0.7% (CI 0.34–1.13) on the lower GI 
disorders. Half a century later, in 2015, twelve times more research was being carried 
out on benign GI disorders. However, while research on the lower GI tract had 
increased 383 times, that on hepatitis eleven times and that on the upper GI tract ten 
times, the number of studies on pancreatitis had risen only five times. These 
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nonparallel changes led to a situation in which only 10.7% (CI 10.27–11.11) of the 
research activity in 2015 was being performed on pancreatitis from among the benign 
GI disorders (Figure 2). Since research on the upper GI tract and hepatitis rose parallel 
to the average increase of the research on the GI diseases, we can assume that the 
great loss of interest in pancreatology was accompanied by a great upturn in research 
in the lower GI disorders, namely, inflammatory bowel disease (IBD) and irritable bowel 
disease (IBS).   
 
 
Figure 2. Inflammatory GI diseases. From 1965 to 2015, the great loss of interest in 
pancreatology was accompanied by a major increase of research in the lower GI 
disorders, namely, IBD and IBS.   
 
2. Research activity on pancreatic cancer has risen slightly 
compared to other GI cancers 
In 1965, among the major malignant GI disorders, research was conducted on the 
different forms of cancer as follows: cancer of the liver: 33.9% (CI 31.89–35.93); the 
stomach: 29.1% (CI 27.18–31.04); the colon: 14.6% (CI 13.05–16.05); the pancreas: 
11.9% (CI 10.55–13.29); and the oesophagus: 10.5% (CI 9.20–11.80). Fifty years later, 
in 2015, twelve times more research was being performed on malignant GI disorders, 
an increase of exactly the same level as that of the studies on the benign GI disorders. 
While the relative research activity on liver and oesophageal cancer did not change, a 
clear decrease was observed in studies on gastric cancer (from 29.1% to 20.2%), with 
the biggest rise found in the research on pancreatic cancer (1.5 times) (Figure 3). 
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Figure 3.  Malignant GI diseases. The biggest increase was found in research activity 
on pancreatic cancer.  
 
3. Research on pancreatitis has decreased compared to that on other 
major pancreatic disorders. 
Since the biggest drop in GI research interest was in the area of pancreatitis, we 
continued our study by analyzing the trends in pancreatic diseases. Here we compared 
the changes of research activity in diabetes, pancreatitis and pancreatic cancer. In 
1965, 71.8% (CI 69.99–73.51) of the research was performed on diabetes, 18.1% (CI 
16.63–19.65) on pancreatitis and 10.1% (CI 8.93–11.29) on pancreatic cancer. 
Although 18 times more studies were being conducted on the pancreas 50 years later, 
the relative interest in pancreatitis had dropped to 5% (CI 4.88–5.28). The relative 
activity did not change very much in pancreatic cancer (from 10.1 to 11.2%); however, 
research interest in the endocrine pancreas rose by 11.9% (Figure 4).  
 
Figure 4. Pancreatic diseases. The relative interest in pancreatitis dropped from 
18.1% to 5%. 
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Analyzing the dynamic of the changes, we can assume that the biggest rise in 
pancreatic research activity in the last five years was in experimental pancreatic 
cancer. However, the number of clinical trials – especially on pancreatitis – started to 
decrease (Figure 5).  
 
 
Figure 5. Dynamic of pancreatic research. The biggest rise of pancreatic research 
activity in the last five years was in experimental pancreatic cancer. However, the 
number of clinical trials – especially on pancreatitis – started to decrease. 
 
4. The USA, Germany and Japan published the highest number of 
articles in pancreatology. 
As stated above, 6,628 articles contained original research on basic or clinical 
pancreatology (involving 7,927 countries). Regarding the continents, 47.8% of all 
participation involved Europe, 28.8% North America, 20.4% Asia and the Middle East, 
1.2% Australia and Oceania, 1.2% South America and 0.5% Africa (Figure 6).  
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Figure 6. Published articles per continent. 47.8% of all the articles came from 
Europe and 28.8% from North America.  
 
In terms of the four subgroups (E-P, E-PC, C-P and C-PC), while Europe has the 
leading role in E-P, C-P and C-PC studies, North America has the highest share in E-
PC research. Among the subgroups, C-P has the lowest proportion of all articles on all 
the continents (Table 2).  
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Table 2. Published articles. The share of the continents in the four research 
subgroups. Europe has the leading role in E-P, C-P and C-PC, while in the E-PC 
research North America has the highest share. Among the subgroups C-P has the 
lowest share of all articles in all continents. 
 
Regarding the location of research, not surprisingly, countries with the largest 
population had an advantage: the USA was involved in the largest number of research 
articles (26.8%), followed by Germany (10.4%), Japan (10.2%) and China (6.4%) 
(Figure 7 and Figure 8). Altogether, these four countries participated in more than 50% 
of the research on pancreatology.  
 
Figure 7. Published articles per country. The USA, Germany, Japan and China 
together account for more than 50% of all published articles in pancreatology. 
21 
 
 
 
Figure 8. Map of published articles. The USA was involved in the largest number of 
research articles, followed by Germany, Japan and China. 
 
Detailed analyses of the four subgroups revealed that the USA led all four subgroups. 
The countries that ranked second in the subgroups were Germany in the experimental 
research groups (E-P and E-PC), China in C-P and Japan in C-PC (Table 3).  
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Table 3. Published articles. The share of the countries in the four research 
subgroups. The USA led all of the four research subgroups, however, the second was 
Germany in the experimental research groups (E-P, E-PC), whereas China had the 
second place in the C-P while Japan in the C-PC group. 
 
5. The density of active pancreatic researchers is highest in the 
Scandinavian countries. 
Comparing the data per population of 10 million, small countries came to the fore. 
Scandinavian countries are clearly the most active in pancreatic research per capita. 
None of the big countries were in the top five (Figure 9).  
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Figure 9. Map of published articles per population. The Scandinavian countries are 
clearly the most active in pancreatic research per capita. 
 
Detailed analysis has also revealed interesting differences between the countries 
(Table 4). E-P research is led by Finland, E-PC by Switzerland, C-P by Denmark and 
C-PC by Sweden.  
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Table 4. Published articles per 10 million population in the four research 
subgroups. When we normalize the number of published articles to 10 M population, 
E-P research is led by Finland, E-PC by Switzerland, C-P by Denmark and C-PC by 
Sweden.  
 
 
6. The USA and the Netherlands are in the forefront in registered 
clinical trials. 
The highest level of evidence is obtained from registered clinical trials. Unfortunately, 
only 13.4% of all trials were registered in our analysis of the period between 1965 and 
2015. With regard to the absolute numbers of registered clinical trials in pancreatology, 
the big countries register the highest number of trials (Figure 10). Comparing registered 
clinical trials per person, Dutch researchers have been the most active, followed by 
Hungary, Denmark and Sweden (Figure 11). The above results are based on 
publication numbers between 1965 and 2015, but three out of these four countries, 
Denmark, Sweden and The Netherlands accompanied by Estonia and Finland had the 
largest number of actively recruiting registered trials per person in August 2012.  
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Figure 10. Map of registered trials. The big countries hold clear leading positions. 
 
Figure 11. Map of registered trials per population. Comparing the registered clinical 
trials per population of 10 million, Dutch researchers are the most active. 
 
7. Multinational and multicentre studies provide the most valuable 
research in pancreatology. 
Detailed analyses showed that there are no big differences between the average 
impact factors (IF) of countries. Countries with a low number of articles, such as South 
Africa and Canada, have the highest average IF. Over 30 countries produced an 
average IF higher than 5 (Figure 12 and 13). Therefore, practically speaking, the quality 
of research is not country-dependent. However, detailed analysis of the articles 
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revealed that there is a strong correlation between the number of countries per study 
and the quality of the article. In a single-nation article, the average IF is 4.652 (± 0.10), 
when only a single centre is involved. However, the involvement of more than six 
centres in a single nation increased the average IF of articles to 7.094 (± 0.37). Notably, 
multicentre and multinational studies achieved the highest average impact 19.278 (± 
2.55) (Figure 14 and 15).  
 
Figure 12. Map of average impact factor/country. There are no big differences between 
the average IF/country. 
 
Figure 13. Average impact factor per country. Over 30 countries achieved an average 
IF higher than 5. Values are expressed as means ± standard error (S.E.M.). 
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Figure 14. Average impact factor by number of centres and nations. Both multicentre 
and multinational approaches increase the impact of the papers. *: p=0.009 vs. single 
centre single nation; **: p˂0.001 vs single centre/single nation; ***: p˂0.001 vs 2-5 
centres/2–5 nations and vs multicentre/single nation; ****: p˂0.001 vs all groups. 
Values are expressed as means ± standard error (S.E.M.) 
 
 
Figure 15. The share of average impact factor categories. There is a strong correlation 
between the number of countries per study and the quality of the article. 
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Discussion 
With regard to gastrointestinal diseases, there is significant morbidity, mortality and, of 
course, spending within national health budgets [10-14]. In the USA, not only are 60–
70 million people affected by such diseases each year, but they also cause around a 
quarter million deaths annually and generate an estimated cost of $150 billion per year 
[12]. There is no specific therapy for many of these diseases, including pancreatitis 
and pancreatic cancer [15-17]. Of course, first, the pathomechanisms of the disease 
should be understood, which might reveal new therapeutic targets and consequently 
might attract the biomedical industry [18-21]. 
The levels of research activity in academia and the biomedical industry are remarkably 
interdependent [22-26]. Gastroenterology is no longer attractive for investment by 
biomedical firms or medical grant agencies [13]. Therefore, here we aimed to hold a 
mirror up to the researchers and funding agencies to better understand the research 
activity in the field. Of course, the hospitalization dynamics and requirements for 
different diseases in the areas of gastroenterology differ. Since 2000, while some 
hospital admissions have decreased for certain diseases (e.g., cholelithiasis by 14%, 
gastro-oesophageal reflux by 32% and alcoholic liver diseases by 5%) and others have 
risen (acute pancreatitis by 30%, Clostridium difficile infection by 237%), the highest 
number of admissions are due to acute pancreatitis (over 250,000/year), with the 
highest annual costs ($2.5 billion) in the USA [12]. A Scottish study revealed a ten‐fold 
rise in the incidence of acute pancreatitis among men, and about half of that among 
women, from 1961 to 1985 [25]. After that, in the following ten years, it further 
increased by 65% [26]. Moreover, the incidence rate of chronic pancreatitis also rose. 
For example, the hospital admission rate for chronic pancreatitis doubled in the UK 
within ten years [27].  
Therefore, needless to say, boosting research activity in the field of pancreatitis is not 
only important medically but also economically. However, despite its great importance, 
pancreatic research suffered the biggest loss of interest in gastroenterology, a trend 
which could be either due to the lower activity in academic research and/or the lack of 
specific therapy (i.e., no income for the companies) for most of the diseases affecting 
either the endocrine or the exocrine pancreas.  
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What did we find and what can we do? 
 
Strengths: It is clear from our analysis that both large and small countries are 
contributing to pancreatic research. The literature on pancreatology is dominated by 
the United States, Germany, China, Japan, Italy and the UK, just like in other scientific 
fields, such as ‘pain’ [28] and ‘oncology’ [29]. The same countries have the highest 
R&D funds, whereas the density of pancreatic research is the highest in the 
Netherlands, Finland, Sweden, Denmark and Hungary. We have observed a positive 
trend in the publication of pancreatic cancer research, although the reason is definitely 
the highest corporate funding share in oncology and multifactorial action plans, such 
as those in the USA and Europe (www.pancan.org, www.eupancreas.com), which 
increase awareness and may influence decision makers and promote grant funding 
[30]. 
 
Weaknesses: There are 50 countries in Europe, but only 23 are actively publishing in 
the field (with more than ten published articles each in 50 years). The majority (84.8%) 
of the articles under analysis represent a single nation, and 39.9% are single-nation 
and single-centre studies with no cooperation with others. Not surprisingly, without 
cooperation, the possibilities for data collection were limited; therefore, only a few high-
quality multinational and multicentre observational clinical trials or RCTs were 
performed [31-36]. It is important to highlight that the Central and Eastern European, 
African, South American and Asian countries are facing the biggest difficulties as their 
sometimes poor infrastructure and lack of resources make them an undesirable 
research partner. Moreover, grant proposals submitted from these countries are 
usually rejected. More than 50% of the European countries (representing more than 
200 million people!) are only slightly involved in pancreatic research, a situation which 
is a huge mistake and luxury in the field. In addition, patient care is also diminished 
since evidence-based guidelines are only published in a few countries in Eastern and 
Central Europe [37-42]. 
 
Opportunities: This analysis provides clear evidence that multicentre, multinational 
cooperation can achieve better-quality trials and higher impact in the field. International 
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patient registries and biobanks should be created to stimulate quality multicentre 
observational trials, RCTs and translational research [43-49]. Importantly, following the 
success of pancreatic cancer action plans that probably contributed to the four-fold rise 
of E-PC research activity in the last few years, the same action should be initiated for 
pancreatitis. 
 
Threats: If research on pancreatitis is to decrease further, journal editors may consider 
pancreatology an even lower priority, thus resulting in fewer publications in top 
journals. Perhaps it almost goes without saying that this will be followed by fewer grants 
and less activity in the field, thus continuing the vicious circle seen in the last 50 years, 
which has resulted in no specific treatment for acute pancreatitis. 
 
Conclusion 
Countries that have the largest biomedical R&D investments, like the USA, Japan, and 
Germany, publish the highest number of scientific papers. Smaller countries with much 
less sources, like Sweden, Finland, Denmark or Hungary, may increase their impact 
by more intense financial and human resource R&D investments and also by 
international co-operations.  
Substantially more academic and other clinical research should be performed in 
gastroenterology providing higher evidence for more therapeutic solutions. Activity in 
pancreatitis research has been rapidly decreasing. These data strongly suggest to 
governments, industry and non-profit organizations that they should consider 
pancreatitis an endangered field of research and sponsor far more international 
networks and academic R&D activities.   
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DEVELOPING A BETTER ENVIRONMENT FOR 
PANCREATIC RESEARCH 
Introduction     
There is still no specific therapy for many of the pancreatic diseases, including acute 
pancreatitis and pancreatic cancer [15-17]. Establishing the diagnosis, preventing the 
progression and treating clinical symptoms are still challenging in chronic pancreatitis 
[50-51]. Pancreatology is a small area within gastroenterology and it is hard to 
individually organize studies, obtain grants, which result in a small amount of studies, 
and those studies are mainly single centre retrospective trials.  
As our previous analysis showed, industrial investments into gastroenterology 
research has been decreasing in the last decade just like the activity in pancreatology 
research, especially concerning pancreatitis. This analysis has also confirmed the well-
known fact that multinational-multicentre trials are of higher quality, providing higher 
evidence and impact, but the share of the multinational-multicentre studies are very 
low. Consequently, there is still much space for improving both the quantity and quality 
of research activity in the field of pancreatology. In this chapter I would like to evaluate 
the possibilities of changing this poor situation and sum up of steps the Hungarian 
Pancreatic Study Group has made as a start for improvement. 
Background 
There are different ways of acquiring information on healthcare performance, disease 
development or treatment details. These methods provide different data quality, and 
evidence levels resulting in different quality of research and publications having 
different impact. The more requirements are set for data quality, the less limitations will 
accompany the research. (Figure 16).  
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Figure 16. The association between the method and quality of research.  
 
The easiest way is to retrospectively analyze data from a single center database, 
national medical information system or hospital discharge data [52-53] or sending out 
questionnaires to institutions [54] or patients [55]. However, retrospective data are 
limited and often insufficient in quantity or quality. 
 
The other way is collecting all cohorts and studies and conduct a meta-analysis. In 
this way we can identify areas where data are missing or insufficient. A recent meta-
analysis [56] used 35 population representative pancreatic cancer cohorts for 
incidence and mortality analysis. These cohorts represented Europe, North-America 
and Asia quite well, but cohorts from Africa, Australia & Oceania and South-America 
were missing from the evaluation.  
Concerning acute pancreatitis, only 10 cohorts were analyzed from 5 countries, the 
USA, the UK, Sweden, Denmark and Taiwan, 6 of the cohorts coming from Northern-
Europe. In case of chronic pancreatitis the situation is even worse, the meta-analysis 
was done on only 3 cohorts collected from Sweden, Denmark and the USA. There 
were little data available both for acute and chronic pancreatitis. 
 
Patient registries are the first step from retrospective research towards good quality, 
high evidence randomized controlled clinical trials. While enrolling patients, there is a 
possibility to include questions usually missing from general medical records. These 
registries are useful in 1) understanding the current practice, 2) comparing the practice 
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with other institutions, countries, 3) following patients, 4) controlling guideline 
compliance, 4) analyzing collected data, writing scientific papers, 5) educating young 
doctors and in consequence of these former actions, 6) improving healthcare. If a 
biobank is connected to the database, genetic analyses also can be performed. 
There are several initiatives of multicenter pancreatic patient registries mainly in the 
USA, UK, Spain, the Netherlands: 1) APPRENTICE (Acute Pancreatitis Patient 
Registry to Examine New Therapies in Clinical Experiences), 32 centres, 12 countries 
have joined, only clinical data, http://caperpancreas.org/beta/index.php/apprentice      
2) INSPPIRE (International Study Group of Pediatric Pancreatitis In Search for a 
cuRE), University of Iowa (Aliye Uc), NIH funded project, 14 centres, 4 countries, 250 
children, clinical data and biological samples [57-58]. 3) EUROPAC (European Registry 
of Familial Pancreatic Cancer and Hereditary Pancreatitis), University of Liverpool (Bill 
Greenhalf), 249 families with chronic pancreatitis and 168 families with more than one 
case of pancreatic cancer [59]. 4) CARE (Dutch Chronic Pancreatitis Registry), 1218 
patients, multicenter, single nation [60]. 5) PanGem-Fam (Spanish registry of hereditary 
pancreatic cancer), 42 families, follow-up, screening program [61]. These registries are 
very important initiatives, but most of them are concentrating on a small area of 
pancreatology or they do not collect biological samples. 
We can conclude that more data are needed and there are no data (or very little) from 
Central and Eastern European countries. Also, there are no large biobanks for genetic 
studies, especially in AP and CP. 
 
As it was confirmed by the previous analysis, clinical trials, especially randomized 
controlled trials provide the highest quality data and evidence level, but unfortunately 
there is a lack of registered clinical trials in pancreatology. 
Aims 
Our aims were to collect clinical data and biological samples prospectively for further 
studies in acute pancreatitis (AP), chronic pancreatitis (CP) and pancreatic cancer 
(PC), to recruit centres in order to increase the quality of the research, to provide a 
database and biobank for pancreatic research open for all participants and to make 
the results widely available, open access. 
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Building on the experiences, findings and joined centres of the patient registries, the 
further aim of the Hungarian Pancreatic Study Group was to plan and conduct 
observational clinical trials and improve the management of pancreatic patients by 
adapting the international evidence-based guidelines and educating doctors and 
students. 
Methods 
Research plan: the research plan should include the research protocol, the research 
questionnaire, the patient information form, the patient informed consent form and the 
participation agreement of the joining centers.  
Ethical approval: For developing a registry and a biobank, a research plan should be 
approved by the Secretary of Medical Research Council, Scientific and Research 
Ethics Committee.  
Recruiting centres: the registry and biobank is open for every institution that is able 
to collect all necessary data. In case an institution intends to join the registry, a signed 
letter of intent and a webpage registration is needed. There must be at least one 
dedicated person in every institution to enroll patients and upload data into the registry.  
Patient enrollment: the patient should be informed on the purpose of the research 
and blood sampling and the Patient Informed Consent Form should be signed before 
any enrollment.  
Data collection: As data registration should be available at the different institutions, 
the HPSG has developed a web-page and a web-based electronic data administration 
system. All forms are available from the website and data upload can be accomplished 
online. 
Collected clinical data: the collected information is different for every diagnosis and 
may include details from the patient’s medical history (pancreatic diseases, other 
diseases, pancreatic disorders in the patient’s family), risk factors (smoking and 
alcohol drinking habits), symptoms and clinical signs, details of physical examination, 
laboratory parameters, imaging examinations, other examinations (histology, cytology, 
functional tests) conservative, endoscopic, surgical, oncological and supportive 
therapy details, complication, etiology. 
Collected samples: the collection, delivery and storing of blood samples and other 
biological samples are processed according to the protocol. 
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Data quality control: there is a four-step controlling of data in the registry. The person 
who uploads data will approve the forms as a first controller then the local professional 
(doctor, who takes part in the trial) needs to check and approve forms, the third control 
is a central administrative control done by the central administrative team of the registry 
and finally the professional supervisor of the registry approves the forms.  
Data and sample access: researchers actively contributing to the biobank and 
registry or collaborating researchers may access to data and samples after a formal 
application with the full scientific proposal, using the HPSG Biobank and Registry 
Project Application Form. The use of samples and data are free of charge and should 
serve research purposes only.  
Publications: any results based on the data of the HPSG Registry for Pancreatic 
Patients, can only be published with the consent of the HPSG. 
Results 
1. Establishing the Registry for Pancreatic Patients 
In 2001 the pancreatic research group in Szeged won a Welcome Trust Initiative 
Research Development Award which allowed to start high quality research in Szeged. 
Seven years hard work resulted in an international presence in basic science in 
pancreatology [62,63]. As a result of the evaluation of the clinical research status in 
Hungary in 2011, it was clear that (1) pancreatic clinical research lacks a national 
organization (study group), (2) a common voice, (3) international visibility, (4) national 
EBM guideline, (5) pancreatic biobank and (6) multicenter clinical trials. To find a 
solution for these problems, the Hungarian Pancreatic Study Group (HPSG) was 
founded in 2011 and started the process of developing a national, then an international 
multicenter network for pancreatic research.  
The process included several steps for network development: the first step was the 
foundation of the National Pancreas Registry including data of acute and chronic 
pancreatitis and pancreatic cancer cases, also including a biobank with blood samples.  
The study data collection was approved by the Secretary of Medical Research Council, 
Scientific and Research Ethics Committee, approval number is 22254-1/2012/EKU 
(391/PI/2012) and in 2016 the permission was extended until 2021. The enrollment of 
patients started in September 2012. The patients are enrolled after written informed 
consent. To involve more and more Hungarian centers it was necessary to individually 
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contact them and organize trainings on patient enrollment and data administration. A 
functional webpage and a data administration system was developed, that made 
possible for the centers to provide data and directly upload them into the database. 
The registry started with one Hungarian center in Szeged, soon, the number of joined 
Hungarian centers and enrolled patients started to grew rapidly, reaching 26 centers 
and 1200 patients in 2014. After 2014 international centres are contributing also to the 
development of the registry. In 2016, 39 institutions from 4 countries are uploading 
data to the AP, CP and PC general registry, 33 institutions from 23 countries to the trial 
database but altogether 99 centres have joined or in the process of joining (Figure 17). 
 
 
Figure 17. Registry for Pancreatic Patients. Joined centres and enrolled patients 
2012-2016  
 
The organization of the 1st and 2nd Conference of the Hungarian Pancreatic Study 
Group (held in Nov 2012 and Dec 2013 in Szeged, Hungary) made it possible to hear 
presentations on the clinical research practice and collaborations in other countries 
(Germany, The Netherlands) to involve professionals in pancreatology in HPSG 
activities, also to present the initiation and development of the National Pancreas 
Registry. 
Going from the West to the East, it became clear, that most of the Eastern and Central 
European countries are in the same situation. Therefore, we strongly believe that our 
experience worth sharing with the others and we also aim to share our web facilities in 
pancreatology to stimulate more research in the field.  
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How to join? 
Registries and prospective clinical trials are open for all centers that are able to provide 
quality data, comply with the protocols and have secured the compliance with the local 
institutional and national ethical requirements. Participation in researches and 
authorship policies in publications are regulated in the protocols that are available on 
the website of the Hungarian Pancreatic Study Group (www.pancreas.hu). 
2. Analyses based on registry data and biological samples 
Based on the HPSG Registry for Pancreatic Patients several genetic and three cohort 
studies have been completed and published. 
 
1. Pancreatic cancer. Multicenter Prospective Data Collection and Analysis by the 
Hungarian Pancreatic Study Group [17] 
There were 338.000 new cases of pancreatic cancer worldwide in 2012, this is 4% of 
all cancers diagnosed. Pancreatic cancer is the 7th among cancer deaths worldwide 
(GLOBOCAN 2012). In Hungary 2545 cases were registered in 2012 and it is the 5th 
in number of cancer deaths (Hungarian National Cancer Registry). The 5 year survival 
is less than 5%. There are limited data available on the management of pancreatic 
cancer, especially in Central and Eastern Europe.  
Therefore we enrolled 354 patients with pancreatic cancer into our registry from 14 
centres between September 2012 and March 2014. The mean age of the population 
was 65.2 years (SD 11.5, range: 23-88 years). 53.4% of the patients were male and 
46.6% were female. Participating centres included gastroenterology, endoscopic, 
oncology and surgical departments. 80% of the patients were enrolled from six 
institutions situated in Szeged (2), Pécs (2), Székesfehérvár and Budapest. Collected 
data included demographics (age, gender), risk factors (alcohol consumption, 
smoking, body mass index, acute or chronic pancreatitis, diabetes mellitus, familial PC 
in the medical history, any pancreatic disease in family history), symptoms and clinical 
signs (fever, abdominal pain, diarrhea, jaundice, weight loss), cancer related data (date 
of diagnosis, location of the tumor, histological type, the method to obtain histological 
information, CA 19-9 level at the time of diagnosis, imaging results confirming 
diagnosis and staging), endoscopic, surgical, oncological and supportive therapy. 
This Hungarian cohort provided useful information on demographics, the frequency of 
recurrent AP and CP in the medical history, histological type, details on endoscopic 
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management of obstructions and independent predictors for overall survival. The 
cohort also showed the areas to improve, namely, much more information is needed 
on interventional, oncological and supportive therapy. 
The article was published in June 2016. 
 
2. Prospective, Multicentre, Nationwide Clinical Data from 600 cases of Acute 
Pancreatitis [64] 
Acute pancreatitis is a serious condition with high mortality and it is a leading cause of 
acute hospitalization for gastrointestinal diseases. There is still no specific therapy for 
the treatment and there were no large, nationwide, prospectively collected AP data on 
the diagnosis and the management of AP. Also, compliance to evidence based 
guidelines are proved to reduce mortality and severity, however this was not validated 
on a large nationwide cohort. The aim of this study was to analyze the management of 
AP on a large population in Hungary and validate the major recommendations of the 
IAP/APA evidence-based guidelines for the management of AP. 
600 patients were enrolled prospectively between January 2013 and January 2015 
from 17 Hungarian centres. In this cohort, 56% of the patients were male and 44% 
were female (Figure 18).  
 
 
Figure 18. Gender and age distribution of the 600 acute pancreatitis cases in the 
Hungarian cohort.  
 
Eighty six parameters were collected including diagnosis and management (physical 
examination, laboratory parameters, imaging), demographics, risk factors, endoscopic 
(ERCP, EUS), surgical and conservative therapy (fluid resuscitation, antibiotic therapy, 
pain management) and complications (pancreatic, organ failure, death). 
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The nationwide cohort of 600 cases of AP has showed the major determinants and 
associations of severity and mortality in AP and also emphasized the importance of 
the compliance to evidence-based guidelines. 
The article was published in October 2016. 
 
3. Chronic pancreatitis. Multicenter Prospective Data Collection and Analysis by the 
Hungarian Pancreatic Study Group [65]. 
Chronic pancreatitis is a progressive inflammatory disease causing irreversible 
structural and functional damage of the pancreas. CP may seriously affect the quality 
of life causing pain and maldigestion. The pathomechanism of CP is still poorly 
understood, and without the classical clinical symptoms, the diagnosis in early stages 
are challenging. There are limited number of prospective cohorts available on the 
management of CP and there was none from Hungary, therefore we aimed to collect 
data from CP patients in Hungary in a prospective manner.  
229 patients were enrolled between 2012 and 2014 from 14 Hungarian centres. The 
mean age of the patients was 54.63 years. 73.8% of the enrolled patients were male 
and 26.2% were female. Data collection included demographics, etiology, risk factors, 
symptoms and clinical signs, laboratory parameters, imaging examinations, 
conservative and interventional therapy and complications. 
The cohort concluded that the first nationwide prospective data collection provided 
important information for improving the treatment of the disease. However, quality of 
data collection on diagnosis details and on the progression of the chronic disease 
should be improved.   
The article is submitted. 
 
4. Genetic analysis CELA3A, CELA3B [66] 
The Hungarian Pancreatic Study Group has organized the collection of biological 
samples together with clinical data for the Registry for Pancreatic Patients. The 
permission for the biobank was obtained in 2012. The biobank is located at the First 
Department of Medicine, University of Szeged. 
Chronic pancreatitis is a progressive, relapsing inflammatory disease of the pancreas 
which often develops in the background of genetic susceptibility. In the study the 
hypothesis was tested that changes in complex formation between human 
proelastases and procarboxypeptidases might alter risk for CP.  
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This genetic study was completed on samples from 225 unrelated patients with CP 
(including 120 with alcoholic CP and 105 with idiopathic CP) and 300 controls with no 
pancreatic disease. Individuals were enrolled to the HPSG Registry for Pancreatic 
Patients from 11 Hungarian centers between 2012 and 2016. 
The study demonstrated that variants affecting amino-acid position 241 in human 
CELA3A and CELA3B are not associated with CP, indicating that changes in complex 
formation between human proelastases and procarboxypeptidases do not influence 
the risk for CP. The observation that intronic variant c.643-7G>T in CELA3B was 
significantly underrepresented in alcoholic CP patients suggests this might be a 
protective variant. 
The article was published in December 2016. 
3. Becoming multinational 
In November 2014, the 3rd Conference of the Hungarian Pancreatic Study Group was 
organized together with the 9th International Symposium on Alcoholic Liver and 
Pancreatic Diseases and Cirrhosis, making the event an excellent occasion to involve 
international participants and the Eastern and Central European Pancreatic Study 
Group was founded. Several Eastern and Central European centers delegated their 
professionals and HPSG had the opportunity to present the development of the 
National Pancreatic Registry, which has become international, just like the multicenter 
observational clinical trials initiated by the HPSG. 
4. Planning and developing observational clinical studies 
The HPSG initiated four multicenter, observational clinical trials, namely:1)  EASY for 
establishing an easily obtainable, accurate clinical scoring system that can stratify 
patients according to the severity of acute pancreatitis in the first 6-12 hours after 
admission, 2) PINEAPPLE to establish a clinical scoring system to evaluate the 
necessity of pancreas enzyme test or imaging examination when a child appears at 
the emergency unit with abdominal pain, 3) APPLE for exploring the course of pediatric 
pancreatitis and specify the genetic background of the disease and 4) PREPAST to 
evaluate the role of preventive pancreatic stents at the early course of acute biliary 
pancreatitis evaluating complications and overall outcome compared to the standard 
ERCP techniques. 
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All of these trials were presented and discussed on an international meeting, received 
the necessary ethical approvals and registered in the ISRCTN trial registry accepted 
by the WHO. The Scientific Committee of the International Association of 
Pancreatology has accepted all four trials to promote them among the members. An 
electronic CRF was developed for all of the trials and all documents, including 
protocols, patient informed consent forms, questionnaires, ethical permissions, are 
available on the HPSG website, not only in Hungarian, English and Russian, but also 
in several other languages. Already 33 international centers have already actively 
contributing to the trials, from 23 different countries (Table 5) and additional 30 
countries have expressed their intent to join, several of them are under the process of 
acquiring the local ethical permission.  
 
 
Country City Institute PINEAPPLE APPLE EASY
Austria Salzburg
Universitätsklinik für Kinder- und Jugendheilkunde 
der Paracelsus Medizinischen Privatuniversität
√
Belarus Gomel Gomel Regional Clinical Hospital √
Czech Republic Ostrava
Centrum péče o zažívací trakt, Vítkovická 
nemocnice a.s. √
Finland Helsinki Helsinki University Central Hospital √
Hungary Balassagyarmat Dr. Kenessey Albert Hospital √ √
Hungary Budapest Heim Pál Children’s Hospital √ √
Hungary Budapest
First Department of Pediatrics and Pediatric Health 
Center, Semmelweis University √ √
Hungary Budapest
Second Department of Internal Medicine, 
Semmelweis University √
Hungary Debrecen
Second Department of Medicine, University of 
Debrecen √
Hungary Debrecen Department of Pediatrics, University of Debrecen √
Hungary Kiskunhalas
Department of Pediatrics, Kiskunhalas 
Semmelweis Hospital √
Hungary Nyíregyháza
 Jósa András University Teaching Hospital of 
County Szabolcs-Szatmár-Bereg √ √
Hungary Pécs
Department of Pediatrics and Pediatric Health 
Center, University of Pécs √
Hungary Pécs First Department of Medicine, University of Pecs √
Hungary Szeged
Department of Pediatrics and Pediatric Health 
Center, University of Szeged √ √
Hungary Szeged First Department of Medicine, University of Szeged
√ √
Hungary Szeged Emergency Unit, University of Szeged √ √
Hungary Székesfehérvár
Department of Pediatrics, St. George University 
Teaching Hospital of County Fejér √
Hungary Szekszárd János Balassa County Hospital √ √
Hungary Veszprém Csolnoky Ferenc Regional Hospital √
Hungary Zalaegerszeg Zala County Hospital √
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Table 5. Countries and institutions actively participating in the observational 
clinical trials of the Hungarian Pancreatic Study Group.  
 
The HPSG in cooperation with the Institute of Genetics, University of Szeged, has 
organized the genetic consultation for those patients who (whose parents) would like 
to know the result of the genetic test done with research purpose in the scope of 
APPLE trial.  
5. Adapting evidence based guidelines 
In 2014 The Hungarian Pancreatic Study Group proposed to prepare Evidence Based 
Guidelines for the management of acute pancreatitis, chronic pancreatitis, autoimmune 
pancreatitis, pancreatic cancer and pediatric pancreatitis. The international guidelines 
were translated and completed or modified where it was necessary by the preparatory 
and consultant team appointed by the HPSG. The guidelines were presented, 
discussed and accepted on a consensus meeting held on 12th September 2014 [38-
42]  
6. Educating young doctors and students 
The HPSG is committed to improve the lives of patients suffering from pancreatic 
diseases. To disseminate the EBM guideline for pancreatic diseases, the HPSG 
printed a hard copy of the published Hungarian guidelines. The book is available at the 
conferences and can be ordered directly from the study group. As the compliance to 
Country City Institute PINEAPPLE APPLE EASY
Italy Padua
Department of Surgery, Oncology and 
Gastroenterology, University of Padua √
Italy Rome S. Andrea Hospital University "Sapienza" √
Japan Tokyo Keio University √
Latvia Riga Pauls Stradins Clinical University Hospital √
Lithuania Vilnius
Vilnius University Hospital Santariskiu Klinikos 
(Santariškių Klinikos) √
Romania Targu Mures Mures County Emergency Hospital √
Romania Timisoara
"Victor Babes" University of Medicine and 
Pharmacy √
Russia Simferopol Medical Academy named after SI Georgievsky √
Russia St. Petersburg Saint Luke Clinical Hospital √
Spain Sant Pere de Ribes Consorci Sanitari del Garrof √
Ukraine Kiev Bogomolets National Medical University √
USA Cincinnati
Division of Gastroenterology, Hepatology and 
Nutrition, Cincinnati Children's Hospital Medical 
Center √
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the guidelines are crucial for a better management of the diseases [67-68], the HPSG 
is organizing training courses and presentations at conferences and at universities. 
Ways to improve 
1. Organizing more clinical trials, both observational trials and RCT’s 
2. Improving existing data collection by data quality control 
3. Following patients in CP from the date of diagnosis  
4. Organize cooperation between gastroenterology, surgery and oncology institutions 
and departments for a better quality data collection in PC 
5. Recruiting more international centers 
 
Conclusions 
Current barriers in pancreatology should be eliminated by an international research 
network, cooperation between pancreatic communities in different countries that will 
result in more and higher quality prospective multicenter observational clinical trials 
and RCTs, EBM guidelines available in more countries, improvement of compliance 
through education, influence on national financing of pancreatology, ultimately in 
quality research. To reach this goal, transparency, trust, visibility and teamwork are 
absolutely essential. The Hungarian Pancreatic Study Group undertakes the task of 
coordination and administrative support and it is open for initiatives and ideas.  
In the future the HPSG/ECEPSG plans to involve more international centers, organize 
multicenter observational clinical studies and randomized clinical trials. 
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New results 
Analyzing the research trends in gastroenterology 
1. From 1965 to 2015, the great loss of interest in pancreatology was accompanied by 
a major increase of research in the lower GI disorders, namely, IBD and IBS.   
2. Among the malignant GI diseases the biggest increase was found in research 
activity on pancreatic cancer.  
3. Concerning pancreatic diseases (pancreatitis, pancreatic cancer, diabetes), the 
relative interest in pancreatitis dropped from 18.1% to 5%. 
4. The USA, Germany and Japan published the most scientific papers in pancreatology 
and this is parallel with the R&D investment shares except for China where the 
investment has increased substantially only in the last few years. 
5. The Scandinavian countries are clearly the most active in pancreatic research per 
capita and this is most probably caused by the higher R&D intensity and human 
resource investments in these countries. 
6. Multicentre and multinational clinical trials provide the highest impact in pancreatic 
research. 
 
Developing a better environment for pancreatic research 
1. Improving the Registry for Pancreatic Patients – data collection, documentation, 
electronic surface, centre enrollment, data analysis. 
2. Participation in data analysis based on the Registry for Pancreatic Patients, resulting 
in published articles. 
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